Clinical trial Recruiting at 1 site Observational Ages 4 to 60

Topical Cyclosporine 1% for Severe Pediatric Ocular Surface Inflammation

Official title: Treatment of Ocular Surface Inflammations With 1% Cyclosporine (Ikervis) Eye Drops

Run by Semmelweis University · NCT07732855 · Data updated 2026-11-12

This study tests whether daily topical Cyclosporine 1% helps children with severe allergic eye inflammation and if it reduces the need for rescue steroids.

Quick facts

Study typeObservational
Ages4 Years to 60 Years
SexAll
Enrollment50 (estimated)
SponsorSemmelweis University
Academic / other
Locations1 site (Budapest, Pest County)
StatusRecruiting
StartedJune 10, 2025
Main results expectedDecember 2026
Study endsDecember 2028
Registry record updatedAugust 3, 2026
Trial IDNCT07732855 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children with severe ocular surface inflammation who are already prescribed topical Cyclosporine 1% as part of routine care and can commit to follow-up visits.

Probably not a fit

Patients unlikely to benefit include those with recent eye surgery or other conditions that preclude accurate ocular surface measurements.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows pediatric patients with severe ocular surface inflammation who are treated with topical Cyclosporine 1% as part of routine care. Participants will use the eye drops daily for several months and have eye exams and tear film assessments at 2–6 week visits. They will document symptoms and any use of rescue steroids in a diary to help gauge safety and potential benefits. Slit-lamp exams, tear film measurements, eyelid and anterior segment evaluations will be performed during follow-up. The study aims to determine safety and whether Cyclosporine 1% lowers rescue steroid requirements.

Why it matters

Potential benefit: If successful, the approach could reduce the need for rescue steroids and improve management of pediatric ocular surface inflammation.

How similar studies have gone: Previous studies in similar inflammatory eye conditions have shown some benefit with topical cyclosporine, but results vary and this setting is observational.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ocular surface inflammatory disease cornea inflammation -keratitis

Exclusion Criteria:

* eye surgery within 1 year, lack of fitness for the objective ocular surface measurments

Where it's running

  • Semmelweis University Department of Ophthalmology
    Budapest, Pest County, Hungary
    Recruiting

Study contacts

  • Principal investigator: Amarilla Barcsay-Veres, MD — Semmelweis University
  • Study coordinator: Lim Lu Hyoun
  • Email: luhyoun21c@gmail.com
  • Phone: +3614591500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.